Minimal Residual Disease in -mutant Non-small-cell Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 10

PMID 36212398

Authors

Nathan T Bain

Yang Wang

Surein Arulananda

Affiliations

Soon will be listed here.

Abstract

Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual disease (MRD). This mini-review explores the mechanistic pathways leading to tumour dormancy, cellular senescence and epigenetic changes involving YAP/TEAD activation. We describe the various approaches of utilising TKIs in combination with agents to intensify initial depth of response, enhance apoptosis and target senescence-like dormancy. This mini-review will also highlight the potential novel therapies under development targeting MRD to improve outcomes for patients with -mutant NSCLC.

Citing Articles

Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis.

Ma L, Zhang J, Dai Z, Liao P, Guan J, Luo Z Front Immunol. 2025; 15:1512349.

PMID: 39872524 PMC: 11770037. DOI: 10.3389/fimmu.2024.1512349.

The two sides of chromosomal instability: drivers and brakes in cancer.

Hosea R, Hillary S, Naqvi S, Wu S, Kasim V Signal Transduct Target Ther. 2024; 9(1):75.

PMID: 38553459 PMC: 10980778. DOI: 10.1038/s41392-024-01767-7.

References

Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen L . Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. Lung Cancer. 2020; 146:358-361. DOI: 10.1016/j.lungcan.2020.05.036. View

Zhong W, Wang Q, Mao W, Xu S, Wu L, Wei Y . Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2020; 39(7):713-722. PMC: 8078324. DOI: 10.1200/JCO.20.01820. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Arulananda S, OBrien M, Evangelista M, Jenkins L, Poh A, Walkiewicz M . A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021; 7(1):122. PMC: 8163735. DOI: 10.1038/s41420-021-00505-0. View

Luo J, Makhnin A, Tobi Y, Ahn L, Hayes S, Iqbal A . Erlotinib and Trametinib in Patients With -Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5. PMC: 8232136. DOI: 10.1200/PO.20.00315. View

Kim E, Jung J, Kim A, Chang Y, Kim S . ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. Neoplasia. 2017; 19(4):354-363. PMC: 5358954. DOI: 10.1016/j.neo.2017.02.008. View

Ball D, Tao Mai G, Vinod S, Babington S, Ruben J, Kron T . Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019; 20(4):494-503. DOI: 10.1016/S1470-2045(18)30896-9. View

Zhong W, Wang Q, Mao W, Xu S, Wu L, Shen Y . Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2017; 19(1):139-148. DOI: 10.1016/S1470-2045(17)30729-5. View

Hata A, Niederst M, Archibald H, Gomez-Caraballo M, Siddiqui F, Mulvey H . Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016; 22(3):262-9. PMC: 4900892. DOI: 10.1038/nm.4040. View

10.

Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K . Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021; 149:14-22. DOI: 10.1016/j.ejca.2021.02.019. View

11.

Prieur A, Peeper D . Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol. 2008; 20(2):150-5. DOI: 10.1016/j.ceb.2008.01.007. View

12.

Fakhri S, Moradi S, DeLiberto L, Bishayee A . Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies. Biochem Pharmacol. 2022; 199:114989. DOI: 10.1016/j.bcp.2022.114989. View

13.

Chudacek J, Bohanes T, Klein J, Benedikova A, Srovnal J, Szkorupa M . Detection of minimal residual disease in lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 158(2):189-93. DOI: 10.5507/bp.2013.019. View

14.

Frisone D, Friedlaender A, Addeo A . The Role and Impact of Minimal Residual Disease in NSCLC. Curr Oncol Rep. 2021; 23(12):136. PMC: 8568856. DOI: 10.1007/s11912-021-01131-w. View

15.

Lochmann T, Floros K, Naseri M, Powell K, Cook W, March R . Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clin Cancer Res. 2017; 24(2):360-369. PMC: 5771805. DOI: 10.1158/1078-0432.CCR-17-1606. View

16.

Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

17.

Ribeiro M, Knebel F, Bettoni F, Saddi R, Sacardo K, Canedo F . Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. NPJ Precis Oncol. 2021; 5(1):5. PMC: 7880994. DOI: 10.1038/s41698-021-00149-4. View

18.

Gu J, Yao W, Shi P, Zhang G, Owonikoko T, Ramalingam S . MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer. 2020; 126(16):3788-3799. PMC: 7381372. DOI: 10.1002/cncr.32996. View

19.

Liu Z, Gao W . Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. Arch Toxicol. 2020; 94(9):3125-3136. PMC: 7423640. DOI: 10.1007/s00204-020-02816-0. View

20.

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View